Verrica Pharmaceuticals Inc. (VRCA)
| Market Cap | 107.71M +141.6% |
| Revenue (ttm) | 37.16M +417.6% |
| Net Income | -17.83M |
| EPS | -1.31 |
| Shares Out | 17.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 81,594 |
| Open | 6.85 |
| Previous Close | 6.95 |
| Day's Range | 6.21 - 6.90 |
| 52-Week Range | 3.28 - 9.82 |
| Beta | 1.55 |
| Analysts | Buy |
| Price Target | 17.00 (+171.13%) |
| Earnings Date | May 12, 2026 |
About VRCA
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of... [Read more]
Financial Performance
In 2025, Verrica Pharmaceuticals's revenue was $35.58 million, an increase of 370.22% compared to the previous year's $7.57 million. Losses were -$17.89 million, -76.64% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for VRCA stock is "Buy." The 12-month stock price target is $17.0, which is an increase of 171.13% from the latest price.
News
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of derm...
Verrica Pharmaceuticals reports Q1 adjusted EPS (41c), consensus (59c)
Reports Q1 revenue $5.02M, consensus $4.52M. “Our first quarter performance reflects accelerating growth in market demand for YCANTH as the new standard of care for the treatment of molluscum contagio...
Verrica Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw record growth in YCANTH demand, with revenue up 25% year-over-year and strong momentum into Q2. The company advanced its clinical pipeline, launched YCANTH in Japan, and is preparing for EU expansion, while maintaining a solid cash position to fund operations into 2027.
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
– Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026, up 12.1% over the previous quarter and 51.3% year-over-year, and has now exceeded 100,000 dispensed...
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verric...
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the ...
Verrica Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
YCANTH continues to drive revenue growth through expanded access and clinician adoption, with a robust pipeline targeting common warts and basal cell carcinoma. Phase III trials for both indications are progressing, supported by strong financials and strategic partnerships.
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of de...
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
WEST CHESTER, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of de...
Verrica Pharmaceuticals Earnings Call Transcript: Q4 2025
2025 saw a dramatic turnaround with over 130% YCANTH revenue growth, a 368% rise in total revenue, and a strengthened balance sheet. Clinical and commercial progress positions the company for further expansion in 2026, with ongoing global trials and new market entries.
Verrica Pharmaceuticals reports Q4 adjusted EPS (51c), consensus (79c)
Reports 4Q revenue $5.092M, consensus $4.52M. “In 2025, Verrica successfully implemented a series of transformational changes that we believe have fundamentally improved the future growth and strategi...
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
– YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenu...
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications fo...
Verrica Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
YCANTH has rapidly gained adoption by addressing a major unmet need in molluscum contagiosum, with expanded access, streamlined distribution, and a growing, collaborative sales force. The pipeline includes a phase III program for common warts and a promising Basal Cell Carcinoma candidate, supporting long-term growth.
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
WEST CHESTER, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases re...
Verrica Pharmaceuticals appoints Chapman as Chief Commercial Officer
Verrica Pharmaceuticals (VRCA) announced the appointment of Chris Chapman as its Chief Commercial Officer. Most recently, Chapman served as Chief Commercial Officer at Dermavant Sciences
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
WEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases re...
Verrica Pharmaceuticals Launches Ycanth for treatment of Molluscum in Japan
Verrica Pharmaceuticals (VRCA) “announced the launch of YCANTH in Japan by its partner, Torii Pharmaceutical Co. Ltd., a wholly-owned subsidiary of Shionogi & Co., Ltd., for the treatment of molluscum...
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
WEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases re...
Verrica announces first patient dosed in program evaluating YCANTH
Verrica Pharmaceuticals (VRCA) announced that the first patient was dosed in December 2025 in the global Phase 3 program evaluating YCANTH for the treatment of common warts. The initiation of…
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opport...
Verrica Pharmaceuticals upgraded to Buy from Hold at Brookline
Brookline upgraded Verrica Pharmaceuticals (VRCA) to Buy from Hold with a $17 price target
Verrica Pharmaceuticals files to sell 14.76M shares of common stock for holders
16:20 EST Verrica Pharmaceuticals (VRCA) files to sell 14.76M shares of common stock for holders
Verrica Pharmaceuticals announces private placement financing of $50M
Verrica Pharmaceuticals (VRCA) entered into a series of securities purchase agreements for a private investment in public equity financing, raising approximately $50 million in gross proceeds, before ...
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
Proceeds will fully retire debt facility from OrbiMed and fund company operations, thereby extending expected cash runway into mid-2027 Financing anchored by Caligan Partners LP and PBM Capital, along...